The organizing committee of the Huntington's Disease Research Group Victoria (HRGV) invites you to attend a Satellite Meeting on Huntington's Disease and Other CAG Repeat Disorders, to be held on the 18th July, 2007, immediately following the IBRO World Congress of Neuroscience. Visit their website for more information.
The following information is provided as a community service.
Your assistance is needed in a research project studying joint stiffness and reflex activity in Huntington's patients. The study aims to improve our understanding of the movement disorder and to provide improved diagnostic techniques and methods for assessing its response to medication. The knowledge gained may ultimately contribute to improvements in therapy.
Patients may attend the Movement Disorders Lab, Neurology Unit, Westmead Hospital or the School of Biomedical Sciences at the Lidcombe campus of the University of Sydney.
Assistance with transport (taxi fare) is available.
To be eligible, you must:
You can contact us by using our phone details below just to ask questions or to arrange a visit. You may also see us in the Neurology Unit at Westmead Hospital on Mondays and Wednesdays.
For more details please contact:
Vimal Stanislaus, Research Student
The University of Sydney
Phone: 0433 561 978 (Mobile)
Dr John Burne, Senior Lecturer
The University of Sydney
Phone: 9351 9316
Email:J.Burne@fhs.usyd.edu.au
Westmead Hospital is conducting a clinical trial of the PREDICT-HD study and is currently seeking men and women to participate in the trial.
Eligible participants:
For more information please contact:
OR
The Huntington Study Group website contains more information about the PREDICT-HD study.
If you reside outside the Sydney metropolitan area and would like to participate in the PREDICT-HD study, financial assistance for accommodation and travel is available. Please contact Jane Griffith for more information.
An update on research being funded by the Association's research grants program is now available.
Technology New Zealand is giving its biggest ever research and development grant to a project that develops the capability in New Zealand to take newly discovered pharmaceuticals to the point of commercialisation.
The funding, totalling nearly $1.7 million, has been awarded to Auckland company Antipodean Biotechnology Limited, which is working with seven of New Zealand's leading research institutes to develop a new chemical entity, mitoquinone, as a treatment for Friedreich's Ataxia and Huntington's Disease. Read more....
Discoveries by a University of California, Irvine team - supported by the Hereditary Disease Foundation - may lead to the first treatment for Huntington's disease, a fatal, hereditary brain disorder.
Reporting in the October 18th issue of the journal Nature, the team announced that they had successfully prevented cell death in a Drosophila fruit fly model they created carrying the HD gene. Most promising of all, the pharmaceuticals they used to protect the fruit fly are currently in clinical trials for treating cancer in humans. Already approved by the Food and Drug Administration for research in a human population, these drugs could rapidly be used in clinical trials for Huntington's disease and other similar progressive, neurodegenerative disorders.
(Archived 12 December 2001) Scientists discovered the gene for Huntington's Disease in 1993, but in all that time, they couldn't explain how the gene leads to the death of a small patch of nerve cells in a key part of the brain.
Now studies from Johns Hopkins Medical Institutions suggest precisely what goes awry in the brain cells marked for destruction. To find out more about this work:
d